Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.GLP-1s are practically everywhere – roughly one in eight U.S. adults take one. But stopping those drugs may come at a cost. That's according to a new study from the Washington University School of Medicine, which was published on Wednesday in BMJ Medicin ...